The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Insulin costs nearly doubled from 2012 to 2016, even as usage remained stable, according to a new analysis from the Health Care Costs Institute (HCCI) — a non-profit funded in part by Aetna, Humana, Kaiser Permanente and UnitedHealthcare. Read More
Both New York City and the Massachusetts Attorney General’s office have set their sights on the family behind Purdue Pharma, alleging the Sackler family continued to push Oxycontin despite detailed knowledge of the overdoses, addiction and deaths the product was causing. Read More
Similarly, Celgene’s blood cancer drug Imnovid/Pomalyst (pomalidomide) saw sales of $513 million in the third quarter, a 23 percent year-over-year increase, and its non-small cell lung cancer treatment Abraxane (paclitaxel) saw revenues increase by 15 percent year-over-year to $288 million. Read More
Bristol-Myers Squibb’s planned acquisition of Celgene this year will dramatically increase BMS’ position in oncology drugs as it absorbs the New Jersey-based company’s portfolio of existing cancer drugs and promising pipeline products. Read More